Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Barclays PLC (BCS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Barclays PLC — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $222.98 (market cap $29.60B), while Barclays PLC trades at $28.1 (market cap $93.87B). The key difference: Barclays PLC is far larger — about 3.2× Alnylam Pharmaceuticals, Inc.'s market cap, and Barclays PLC pays a 2.19% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | BCS | |
|---|---|---|
Market Cap | $29.60B | $93.87B |
Sector | Health | Financials |
52-Week High | $491.22 | $28.56 |
52-Week Low | $205.48 | $19.36 |
Enterprise Value | $27.56B | — |
Dividend Yield | — | 2.19% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Barclays PLC
Barclays is a universal bank headquartered in the United Kingdom. It operates via two principal segments
Read more on BCS →
